A number of possible chemotherapy agents can be selected, but most involve the platinum-based chemotherapy drug called cisplatin.Other treatments include percutaneous ablation and chemoembolization. The most widely used ablation techniques for lung cancer are radiofrequency ablation (RFA), cryoablation, and microwave ablation. Ablation may be an option for patients whose tumors are near the outer edge of the lungs. Nodules less than 1 cm from the trachea, main bronchi, oesophagus, and central vessels should be excluded from RFA given high risk of complications and frequent incomplete ablation. Additionally, lesions greater than 5 cm should be excluded and lesions 3 to 5 cm should be considered with caution given high risk of recurrence. As a minimally invasive procedure, it can be a safer alternative for patients who are poor candidates for surgery due to comorbidities or limited lung function. A study comparing thermal ablation to sublobar resection as treatment for early stage NSCLC in older people found no difference in overall survival of the patients. It is possible that RFA followed by radiation therapy has a survival benefit due to synergism of the two mechanisms of cell destruction. Advanced/metastatic NSCLC
The treatment approach for people who have advanced NSCLC is first aimed at relieving pain and distress (palliative), but a wide variety of chemotherapy options exists. These agents include both traditional chemotherapies, such as cisplatin, which indiscriminately target all rapidly dividing cells, and newer targeted agents, which are more tailored to specific genetic aberrations found within a persons tumor.
Positive antibodies include:Antinuclear antibody (ANA)
Anti-smooth muscle antibody (ASMA) - 65% of people
Anti-actin antibodies
Anti-mitochondrial antibodies - rare except for overlap syndromes with primary biliary cholangitis
Anti-soluble liver antigen/liver pancreas antibody antigen - 20% of people
Anti-double stranded DNA - 30% of people
Atypical perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA)
Type 2 autoimmune hepatitis. Positive antibodies include:Liver Kidney Microsomal antibody (LKM-1)
Anti-liver cytosol antibody-1 (SLC-1)
Autoantibody negative autoimmune hepatitis.Lack positive ANA, ASMA, LKM-1, etc. antibody panels but present with clinical features of autoimmune hepatitis that resolve with standard treatment. Differential diagnosis
Other diagnoses to consider include conditions that may cause acute hepatitis or chronic liver inflammation that may be accompanied by cirrhosis:

Other autoimmune diseases that involve the liver:
Primary biliary cholangitis - the presence of isolated elevated AMA antibodies usually signifies primary biliary cholangitis rather than autoimmune hepatitis and further diagnostic evaluation is needed. Overlap syndromes - autoimmune hepatitis may present similarly to primary sclerosing cholangitis but people with primary sclerosing cholangitis have stricturing and dilatation of intra/extra-hepatic ducts while people with autoimmune hepatitis generally have a spared biliary tree.